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Abstract
Reliable and accurate reference intervals (RIs) for laboratory analyses are an integral part of the process of correct interpretation of clinical labora-
tory test results. RIs given in laboratory reports have an important role in aiding the clinician in interpreting test results in reference to values for 
healthy populations. Since the 1980s, the International Federation of Clinical Chemistry (IFCC) has been proactive in establishing recommendations 
to clarify the true significance of the term ‘RIs, to select the appropriate reference population and statistically analyse the data. The C28-A3 guideline 
published by the Clinical and Laboratory Standards Institute (CLSI) and IFCC is still the most widely-used source of reference in this area. In recent ye-
ars, protocols additional to the Guideline have been published by the IFCC, Committee on Reference Intervals and Decision Limits (C-RIDL), including 
all details of multicenter studies on RIs to meet the requirements in this area. Multicentric RIs studies are the most important development in the 
area of RIs. Recently, the C-RIDL has performed many multicentric studies to obtain common RIs. Confusion of RIs and clinical decision limits (CDLs) 
remains an issue and pediatric and geriatric age groups are a significant problem. For future studies of RIs, the genetic effect would seem to be the 
most challenging area. 
The aim of the review is to present the current theory and practice of RIs, with special emphasis given to multicenter RIs studies, RIs studies for pe-
diatric and geriatric age groups, clinical decision limits and partitioning by genetic effects on RIs.
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In the mid 20th century, Grasbeck and Fellman 
published a paper entitled ‘Normal Values and Sta-
tistics’ as an initial study in the field of reference 
intervals (RIs) (1). This was followed by a presenta-
tion by Grasbeck and Sais on ‘Establishment and 
Use of Normal Values’ (2). In subsequent years it 
was realized that the terminology of ‘normal val-
ues’ was not adequate and even partially incor-
rect, so the term ‘reference values’ came into use. 
From 1987 to 1991, the International Federation of 
Clinical Chemistry (IFCC) published a series of 6 pa-
pers, in which it was recommended that each lab-
oratory follow defined procedures to produce its 
own reference values (3-8). Although there were 
very important developments and implementa-
tions between the 1990s and 2008 (9-12), the C28-
A3 guideline, published in 2008 by CLSI and IFCC 
constituted the most significant step in the devel-
opment of RIs and is still in current use (13). This 
guideline entitled ‘Defining, Establishing, and Veri-
fying Reference Intervals in the Clinical Laborato-
ry’ provides the necessary steps mainly for the se-
lection of reference individuals, pre-analytical and 
analytical considerations, and analysis of reference 
values for a RI establishment study. In the C28-A3 
guideline, in order to perform a multicenter RI 
study, criteria need to be satisfied described with 
the topics (i.e. a priori selection of reference sub-
jects, clear definition of the pre-analytical phases, 
demonstration of traceability of results and stan-
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dardization, and well defined quality control pro-
gram with clear criteria) (13). In recent years, knowl-
edge additional to the Guideline has come from 
the multicenter RI studies, especially those con-
ducted by IFCC.
Interest has been renewed in the topic as a result 
of the following regulatory initiatives in the last 
two decades (14): according to the European Di-
rective 98/79 on in vitro diagnostic (IVD) medical 
devices, diagnostic kit manufacturers are obliged 
to supply their clients with appropriate reference 
RIs for use with their assay platforms and reagents 
(15), and the International Organization for Stand-
ardization (ISO) 15189 standard for clinical labora-
tory accreditation states that each laboratory 
should periodically re-evaluate its own RIs (16). In 
the present-day era of evidence-based medicine, 
there is still a big gap between theory and practice 
with respect to the application of RIs as decision-
making tools, despite the mandatory require-
ments (14). Through the continuing and increasing 
studies initiated by the IFCC, Committee on Refer-
ence Intervals and Decision Limits (C-RIDL) in re-
cent years on multicenter RI studies, it has been 
possible to derive ‘common’ or ‘harmonized’ RIs 
on a national level from multicenter studies that 
follow a common protocol (17). The C-RIDL recent-
ly published two papers including a protocol and 
comprehensive standard operating procedures 
(SOPs) for multicenter RI studies (18), with indica-
tion of the utility of a panel of sera for the align-
ment of test results among laboratories in multi-
center studies (19).  
For pediatric and geriatric Rıs, the challenges are 
even greater since samples from reference individ-
uals are difficult to obtain (20). This problem can 
be overcome by gathering large populations of 
reference individuals (21). Another point of discus-
sion is the confusion which arises from RIs and 
clinical decision limits (CDLs). Reference values are 
calculated specific to health whereas CDLs indi-
cate sensitivity to disease (22). 
The aim of the review is to present the current the-
ory and practice of RIs together with a detailed 
evaluation of the most recent multicenter studies, 
an assessment of the RIs of the pediatric and geri-
atric age groups, which is still regarded as a prob-
lem in this area, a clarification of the confusion 
which arises from the use of CDLs and future pos-
sibilities based on partitioning by genetic informa-
tion to generate RIs.
Reference intervals; the theory and the 
practice
RIs are derived from reference distribution, usually 
of 95% interval, and describe a specific popula-
tion. The classical cascade is defined from refer-
ence individuals, a reference sample group, refer-
ence values, reference distribution, reference lim-
its and RIs. The reference individuals form the ref-
erence sample group for measurement of the val-
ues from the reference population. Through statis-
tical analysis of the distribution of the obtained 
values, the reference limits are calculated. These 
limits then define the RI (3).
The selection of reference individuals using a sam-
ple questionnaire is explained in detail in the CLSI/
IFCC document, C28-A3 (13). Health is a relative 
condition lacking a universal definition. The desig-
nation of good health and determination of nor-
mality for a candidate reference individual may in-
volve a variety of examinations, such as a history 
and physical and/or certain clinical laboratory 
tests. The exclusion and partitioning criteria can 
be implemented appropriately through a well-de-
signed questionnaire. Exclusion criteria are fea-
tures which prevent the individual from being in-
cluded in the reference sample. Although some 
criteria, such as alcohol, tobacco and some envi-
ronmental factors, may be potential exclusion cri-
teria, amounts of consumption of alcohol and to-
bacco can be recorded in detail on the sample 
questionnaire and the effects are evaluated statis-
tically, primarily using multiple regression analysis 
(MRA) (18,19). Written informed consent from par-
ticipants is needed from each reference individual 
who agrees to participate in the study. The con-
sent form should state clearly that laboratory per-
sonnel are allowed to obtain specimens, and to 
use the associated laboratory values and question-
naire information for the determination of RIs (13).
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In the a priori sampling approach, exclusion crite-
ria are applied before sampling collection and it is 
the more appropriate approach when the biology 
of an analyte is known. In a posteriori sampling, the 
exclusion criteria are applied after the sampling. 
Both of these methods are known as direct sam-
pling, which is the primary recommendation of 
the IFCC. Ideally, RIs are determined on the basis of 
a healthy population using direct methods (4). 
However, indirect methods, which are also known 
as data mining, based on previous laboratory data 
can also be useful (23). Various methods may be 
used for the selection of a group of healthy indi-
viduals from a general hospital population and 
reference values are calculated from hospital data 
using statistical methods, such as Bhattacharya 
analysis (24) and some modifications of the meth-
od (25,26). There is opposition to this approach 
from some, as there is insufficient knowledge of 
the subjects and reliance on statistical methods to 
exclude the unhealthy subjects as explained in 
C28-A3. It has also been emphasised that as there 
is little control of the pre-analytical and analytical 
conditions, the indirect approach could be used 
for local situations or difficult groups of subjects 
such as neonates, children or the elderly, or as a 
means to confirm the goodness of the selected RI 
(27). Other researchers favour the indirect method 
as the results are clinically relevant and much sim-
pler for an individual laboratory to implement 
than the time-consuming direct a priori method, 
which requires considerable data and professional 
input (28,29).
Pre-analytical and analytical aspects must be tak-
en into consideration in the implementation of a 
RI study. Generally, the pre-analytical consider-
ations involve biological (i.e. sampling time in rela-
tion to biological rhythms, fasting or non-fasting 
and physical activity) and methodological factors 
(i.e. sample collection techniques, type of addi-
tives, with or without tourniquet and sampling 
equipment, specimen handling, transportation, 
time and speed of centrifugation, and storage 
conditions). For reproducibility and standardiza-
tion, it is essential that the pre-analytical aspects 
are accurately defined and described as the prean-
alytical phase is known to have the highest errors 
in the total test process (30). Because of the impor-
tance of harmonizing pre-analytical phase of the 
total testing process, an effort has been made by 
the European Federation for Clinical Chemistry 
and Laboratory Medicine (EFLM) Working Group 
for Preanalytical Phase (WG-PRE) to support the 
worldwide harmonization of color coding for 
blood collection tube closures (31,32). EFLM, WG-
PRE believes that such harmonization would re-
duce pre-analytical errors and substantially im-
prove patient safety (32).
Analytical aspects include the analytical variability 
of the method used for the measurement, equip-
ment/instrumentation, reagents, calibration stan-
dards, and calculation methods. Different com-
mercial methods may be used in a trueness-based 
approach to the reference measurement system 
providing results traceable to the system and thus, 
comparable results can be produced in clinical 
laboratories. When performing a RI study, the ref-
erence measurement systems and standard refer-
ence materials are of great importance to ensure 
traceability of the test results in comparisons (33).  
Calculation of RIs includes parametric and non-
parametric calculation methods, detection of out-
liers, partitioning, and confidence intervals. The 
lower reference limits are estimated as the 2.5th 
percentile and the upper limits as the 97.5th per-
centile of the distribution of test results for the ref-
erence population. 5% of all results from healthy 
people will fall outside of the reported RI and as 
such will be flagged as being ‘abnormal’. In the 
parametric calculation method, there is an as-
sumption that the observed values, or some math-
ematical transformation of those values, follow the 
Gaussian or ‘‘normal’’ probability distribution. The 
reference values of many analytes do not display 
Gaussian distribution, so the parametric method 
can be applied after data transformation. The 
most suitable transformation method must be se-
lected (e.g. logarithmic, power or some other func-
tion) and testing is then applied to establish 
whether the transformed reference values con-
form to Gaussian distribution. The nonparametric 
method of estimation does not assume the proba-
bility distribution of the observed reference values 
(7). Although the C28-A3 recommends the non-
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parametric calculation method, the RIs calculated 
by the parametric and nonparametric methods 
were compared in the recent IFCC, C-RIDL study 
which concluded that the results of the two meth-
ods are very close and parametric methods can 
also be used as a first choice (13). 
Whichever method is used in the calculation of the 
RIs, detection and exclusion of the outliers are very 
important to obtain reliable RIs. A simple but ef-
fective method for the detection of outliers is vi-
sual inspection of the data. The most common 
method is the D/R method proposed by Dixon (D: 
the absolute value of the difference between the 
suspected outlier and the next or proceeding val-
ue, R: the entire range of the observations) (34). If 
the D/R ratio is more than 1/3, the outlier is dis-
carded. However, this method is not very sensitive 
when there is more than one outlier. The Horn us-
ing Tukey method is a more sophisticated method, 
which includes Box-Cox transformation of the data 
to obtain Gaussian distribution followed by identi-
fication of the outliers in interquartile ranges (IQR: 
Q3-Q1; Q1: lower quartile, Q3: upper quartile). At 
levels of < Q1 - 1.5 IQR and / or > Q3 + 1.5 IQR, the 
outliers are discarded (35,36). The latent abnormal 
value exclusion (LAVE) method proposed by Ichi-
hara et al. (37) is a secondary exclusion method to 
exclude possibly abnormal results hidden within 
the reference values. This method is an iterative 
approach for the derivation of multiple reference 
RIs simultaneously, when no exclusion of values 
has been made in the initial computation of the 
RIs. The algorithm then uses those initial values of 
RIs to judge the abnormality of each individual’s 
record by counting the number of abnormal re-
sults in tests other than the one for which the RI is 
being determined. Several statistical methodolo-
gies have been proposed to be able to make the 
extremely important decision of whether or not to 
separate different groups. 
The most widely-used partitioning method is that 
of Harris and Boyd, in which the means and stan-
dard deviations of the subgroups are considered 
as a separate different standard deviation that may 
produce different limits (38). However, this meth-
od is only appropriate for analytes with a Gaussian 
distribution with subclasses, where the values are 
of similar size and standard deviation. A similar 
method was proposed by Lahti et al. allowing the 
estimation specifically of the percentage of sub-
jects in a subclass outside the RIs of the entire 
population in any situation (39,40). More recently, 
Ichihara and Boyd recommended a partioning 
method on the basis of the magnitude of the stan-
dard deviations of test results named standard de-
viation ratio (SDR) (37). An SDR greater than 0.3 
can be regarded as a guide for the consideration 
of partitioning reference values. This method is 
based on two or three level nested analysis of vari-
ance (ANOVA). Sensitivity of the population based-
RIs can be increased and thereby, the usefulness of 
RIs is improved by stratification of age, gender, 
race, ethnicity and lifestyle. Stratification by age 
and gender is the minimum pre-requisite and oth-
er means include race, ethnicity, body mass index 
or nutritional habits (41). 
In the IFCC publication in 1987 (7), it was recom-
mended that reference limits should always be 
presented together with their 90% confidence in-
tervals (CIs). The CI is a range of values including 
the true percentile (e.g. the 2.5th percentile of the 
population) with a specified probability, usually of 
90% or 95%, as the ‘confidence level’ of the inter-
val. In the C28-A3 guideline, non-parametric CIs 
are given from the observed values corresponding 
to certain rank numbers from Reed et al. (42). Al-
though one can theoretically determine 95% RIs 
with a lower number (as few as 39 samples), it is 
clearly recommended that at least 120 subjects are 
required to calculate the CIs of the lower and up-
per RIs in this guideline (13). Horn and Pesce (43) 
proposed a ‘robust method’ method based on 
transformation of the original data according to 
Box and Cox (44) followed by a ‘robust’ algorithm 
giving different weights to the data, depending 
upon their distance from the mean. This method 
can provide the reference limits from a limited 
number of observations using only 20 subjects 
(45). However, a robust method with such a small 
number of reference subjects (e.g. N = 20) cannot 
provide an acceptably narrow set of confidence 
limits. A small number of subjects can lead to un-
certainty of calculated reference limits revealed by 
the width of its CIs. To calculate the 90% CIs around 
http://dx.doi.org/10.11613/BM.2016.001 Biochemia Medica 2016;26(1):5–16 
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the limits, it is possible to use ‘the bootstrap meth-
od’ which is a ‘resampling’ method and creates a 
‘pseudosample’ from the data. The RI is derived 
from each pseudosample and the process is re-
peated many times (1000 - 2000) yielding a distri-
bution of lower and upper RIs (43). From this distri-
bution, 5th and the 95th quantiles may be used to 
determine the 90% CI for each limit. A critical 
drawback of this approach is that the 90% CIs can 
be very wide if the sample size is small (at least 80 
individuals are needed to obtain acceptably small 
90% CIs) (14). 
If a clinical laboratory changes the method used or 
wishes to apply RIs established by another labora-
tory which has used a different method, transfer-
ence of the RIs can be implemented, rather than 
collecting samples from reference individuals to 
establish a RI for the new method. If the new 
method has similar imprecision and known inter-
ferences, uses the same or comparable standards 
or calibrators, and provides values that are accept-
ably comparable, the RIs can be transferred by 
method comparison based on linear regression 
analysis. In addition, the question of transference 
becomes one of comparability of the reference 
population (46).
The C28-A3 guideline allows for subjective valida-
tion of a RI by laboratory assessment of popula-
tion demographics and pre-analytical and analyti-
cal parameters. This guideline recommends that 
each laboratory adopts existing RI values by per-
forming an analysis to validate the transference of 
a RI reported by a manufacturer or other donor 
laboratory. The acceptability of the transfer may 
be assessed by examining a small number of refer-
ence individuals (N = 20) from the receiving labo-
ratory’s own subject population and comparing 
these reference values to the larger, more ade-
quate original study (13). If no more than 2 of the 
20 samples (or 10% of the test results) fall out of 
the range of the existing RI, it may be adopted for 
use, at least provisionally (13). If more than 2 of the 
20 samples fall outside these limits, a second 20 
reference specimens 20 should be obtained. If no 
more than 2 of the 20 samples fall out of the range 
of the existing RI, it may be adopted for use. If 
three or more again fall outside these limits, the 
user should re-examine the analytical procedures 
used and consider possible differences in the bio-
logical characteristics of the two populations sam-
pled (13). 
Intra- and inter-individual biological variability of 
the subjects within the reference population may 
influence the determination of that RI. In 1974, it 
was demonstrated by Eugene Harris that only 
when intra-individual variability (CVI) is greater 
than inter-individual variability (CVG), (e.g. CVI / 
CVG > 1.4) does the distribution of values from any 
individual cover much of the RI (47). In contrast, 
with the common occurrence of CVI / CVG is < 0.6, 
the dispersion of values for an individual will span 
only a part of the population-based RIs. Thus, the 
RI will not be sensitive to changes for that individ-
ual and, on average, for any individual and in this 
case, subject-based RIs are considered. In cases 
where the reference population is a single subject, 
that person may serve as a reference for himself or 
herself, and these are known as ‘individual RIs’. 
This approach is quite simple and requires the col-
lection of several samples from the same individu-
al (48). The ‘‘reference sample’’ is now replaced by 
a set of results belonging to the single individual, 
assumed to have been collected when he or she 
was in a steady state (49). However, data for statis-
tical analysis are very different: in the individual 
approach, few observations are usually available. 
In addition, they may be collected in a defined or-
der and may not be mutually independent. The re-
sults of measurements on these samples for a giv-
en analyte will produce a temporal series, forming 
a baseline against which future results will be 
judged. A fundamental issue is the number of 
samples needed to define the baseline value. This 
depends upon the biological variability of the ana-
lyte, its analytical reproducibility and the applied 
mathematical procedures (49).
Multicenter reference interval studies 
The requirement that each clinical laboratory pro-
duce its own RIs is practically impossible for most 
clinical laboratories. The selection and recruitment 
of a sufficient number of reference subjects is dif-
ficult, time-consuming, and costly. Although some 
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laboratories have performed local studies for their 
own use, there have also been multicenter studies 
performed with considerable numbers of subjects 
to establish useful RIs by laboratories in the Nordic 
countries (50,51), Spain (52), Australia (53,54), Asia 
(55,56) and Turkey (57). As common standardiza-
tion and traceability are crucial during production 
of reference values, each step of pre-analytical, an-
alytical and statistical application follows a well-
defined protocol. In recent years, C-RIDL has been 
devoted to the determination of Common or Har-
monized RIs (58). A study was made of the meas-
urement of three enzymes (aspartate aminotrans-
ferase - AST, alanine aminotransferase - ALT and 
gamma-glutamyltransferase - GGT) measured 
with commercial analytical systems according to 
the standard methods recommended by the IFCC 
(59). Analysis was made of patient’s sera from Italy, 
China, Turkey and the Nordic countries, and it was 
concluded that for AST and ALT, the use of com-
mon RIs appears possible. However, significant dif-
ferences were observed in GGT between popula-
tions, so worldwide RIs for GGT would not seem to 
be applicable (59). 
The ongoing Worldwide Project involving many 
countries, which was initiated by C-RIDL, aimed to 
derive reliable country-specific RIs through multi-
center studies. With the implementation of a com-
mon protocol and SOPs, the utility of a panel of 
sera was indicated for the alignment of test results 
among laboratories in multicenter studies (60). 
The two most recent papers published by the C-
RIDL include this strategy for the alignment of test 
results for the derivation of RIs (18,19). The require-
ments for conducting the multicenter study, phase 
by phase, are described in a new protocol which 
recommends that a practically attainable target 
sample size from each country is set at a minimum 
of 500, which is more than double the previously 
recommended minimum in the C28-A3 (240; 120 
male and 120 female). The other prerequsites of 
multicenter studies can be summarized as a priori 
selection of reference subjects (i.e. inclusion-ex-
clusion criteria, ethnicity and questionnaire), a 
clear definition of pre-analytical phases (i.e. blood 
collection, sample proccesing, storage and trans-
portation), a clear definition of analytical phases 
(i.e. requirements for the central laboratories and 
the measurements, quality control, standardiza-
tion of the assay and cross-comparison of values) 
and the statistical procedures for data analysis and 
reports of the results (i.e. validation of data, analy-
ses of sources of variation, partitioning criteria and 
derivation of RI) (18). This should ensure that coun-
try-specific RIs are obtained in a more reproduci-
ble manner. In addition to ethnic origins, other 
items were included in the questionnaire to obtain 
more quantitative information regarding alcohol 
consumption, physical activities, menstrual cycle, 
and medications to ascertain how these factors in-
fluence test values. Overall, the procedure for 
standardization of test results is of the utmost im-
portance, and all centers need to comply when 
dealing with standardized analytes. The require-
ments of the central laboratory are also described 
in detail, including the method of cross-check test-
ing between the central laboratory of each coun-
try and the local laboratories before the RIs can be 
applied (18). In the protocol for multicenter studies 
(18), cross-check testing is recommended to con-
vert the RIs obtained from the multicenter study 
by the centralized assay to the values of each par-
ticipating laboratory. The linear structural relation-
ship (reduced major axis regression) is used to con-
vert the RIs. A cross comparison study with anoth-
er laboratory is an approach to compare the labo-
ratories participating in the multicenter study, us-
ing a panel of sera from healthy individuals, and 
recalibrating the results based on regression anal-
ysis, especially in cases where there are no stand-
ardized materials for harmonization of test results 
(18,19,61). The steps for the scheme of a multicent-
er study when all the samples from healthy indi-
viduals are collected in the participating laborato-
ries and sent to the central laboratory for analysis 
are summarised in Table 1. It should be noted that 
when each participating laboratory acts as a cen-
tral laboratory, and collects and analyzes the sam-
ples, all actions including the standardization of 
the analytical phase should be the responsibility 
of each laboratory.
Once RIs have been obtained from a multicenter 
study, the next step in the transference process 
and potential adoption of an interval is validation 
http://dx.doi.org/10.11613/BM.2016.001 Biochemia Medica 2016;26(1):5–16 
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of the proposed RI, which takes account of pre-an-
alytical, analytical, and local population differenc-
es (61). An alternative approach for adopting a RI 
can be done by the indirect method using the lab-
oratory’s existing data which is verification of a RI. 
This approach can be a potential tool for further 
harmonization of RIs (62).
Reference intervals and clinical decision 
limits
The RIs are descriptive of a specific population and 
are derived from a reference distribution (usually 
95% interval), whereas CDLs are thresholds above 
or below which a specific medical decision is rec-
ommended and are derived from Receiver Operat-
ing Characteristic (ROC) curves and predictive val-
ues (63). CDLs are based on the diagnostic ques-
tion and are obtained from specific clinical studies 
to define the probability of the presence of a cer-
tain disease or a different outcome. These limits 
lead to the decision that individuals with values 
above or below the decision limit should be treat-
ed differently. CDLs are defined by consensus and 
vary among different populations. It is important 
that RIs are not confused with CDLs (64). To avoid 
confusion, the C28-A3 recommended reporting 
decision limits or RIs but not both, with a clear in-
dication of which has been used. However, in the 
report example of the C28-A3, in the section of the 
medical decision limits, the CDLs of total choles-
terol and high-density lipoprotein (HDL) cholester-
ol have been given in the same column as the RIs, 
which is confusing on the basis of terminology 
(13). Although highlighted at the bottom of the re-
port sample of C28-A3, it has been noted that HDL 
cholesterol > 1.04 mmol/L and total cholesterol < 
5.17 mmol/L are the recommendations by National 
Cholesterol Education Program. However, it may 
still be confusing because the given values are in 
the RIs column and they are CDLs, but not RIs. It is 
known that lipids (e.g. total cholesterol, HDL cho-
lesterol) have well-defined CDLs. In the case of 
HDL cholesterol, decision limits can be used to cat-
egorize people as having increased risk (< 1.036 
mmol/L) or decreased risk (> 1.554 mmol/L) for 
coronary artery disease based on data from large 
population studies (65). However, in recent years, 
C-RIDL has also supported the estimation of RIs for 
parameters which have clearly-defined CDLs, since 
RIs are specific for the characteristics of the popu-
lation. For example, it is well-established that the 
Turkish population has a high prevalence of coro-
nary heart disease associated with some known 
risk factors (66). Turks have distinctively low con-
centrations of HDL cholesterol, associated with el-
evated hepatic lipase activity and fasting triglycer-
idemia (67). It has also been reported that genetic 
and environmental factors are important in modu-
lating HDL cholesterol concentrations in Turks (68). 
Therefore, it would be better to report the popula-
tion-based RIs only in the RI column in the labora-
tory results, and to state the CDL clearly as a com-
ment in the laboratory report, for example at the 
bottom of the report when a parameter has well-
defined CDLs in the report. 
Pediatric and geriatric reference intervals
As the concentrations of many routinely measured 
analytes vary significantly with growth and devel-
opment, the use of inappropriate pediatric RIs can 
result in mis-diagnosis and mis-classification of 
disease. Establishing RIs can be challenging as the 
ideal RIs should be established based on a healthy 
population and stratified for key covariates includ-
ing age, gender and ethnicity, but this requires the 
collection of large numbers of samples from 
healthy individuals (69). It is well known that the 
determination of pediatric RIs is an extremely dif-
ficult task, primarily because of ethical limitations 
related to blood drawing in very young children 
and neonates. The most significant step in this 
area has been taken by Adeli et al. in the CALIPER 
(CAnadian Laboratory Initiative in PEdiatric Refer-
ence Intervals) Project, which is a collaboration be-
tween multiple pediatric centers across Canada, 
that aims to address the current gaps in pediatric 
RIs and has established a database of age- and 
gender-specific pediatric RIs (70). Recently, the 
CALIPER study demonstrated the relationship be-
tween Abbott Architect assays and four other 
commonly used assays (Beckman Coulter, Ortho 
Vitros, Roche Cobas, and Siemens Vista) for a wide 
Biochemia Medica 2016;26(1):5–16  http://dx.doi.org/10.11613/BM.2016.001 
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The total testing process





1. Organization of the study
Establishing the inclusion and exclusion criteria
Informing each laboratory of the sample size
Deciding the essential items in the questionnaire and distributing to 
all participating laboratories
Communicating with the participating laboratories and informing 
about the procedures (e.g. blood collection and preparation of the 
serum samples) to standardize the pre-analytical phase in each 
laboratory #
2. Using the same protocol in each laboratory (e.g. selection 
and preparation of the volunteers, blood collection and sample 
preparation) #,*
3. Transportation of the samples to central laboratory *






1. Using a reference measurement system, certificated reference 
materials/value assigned sera, standardization of the assays #
2. Quality control of the assays #,*
3. Analyzing all the samples #





1. Reporting of the test results to each laboratory #
2. Data analysis and derivation of the RIs (common RIs, if it’s possible) 
#
3. Reporting of cross-check results and the RIs for each of the local 
laboratory #
4. Using the calculated RIs #,*
RIs - Reference intervals.
Table 1. The scheme for multicenter reference interval studies.
spectrum of biochemical markers (71). The pediat-
ric health survey in Germany (KiGGS) is an another 
excellent example in this area (72). As these direct 
studies were well conducted and of large sample 
size, the current problems in pediatric RIs could be 
resolved through evaluation and application of 
the findings. However, as an alternative, indirect 
methods can be used for the pediatric group as 
recommended in the C28-A3 (13,73). 
The major difficulty in obtaining geriatric RIs is in 
the selection of healthy individuals as most sen-
iors do not meet the criteria of the C28-A3. The 
width of the reference range is altered by factors 
such as the regular use of medications or unrecog-
nized subclinical diseases. Therefore, it becomes 
very difficult to differentiate the effects of age, ag-
ing or a pathological condition. Although there 
has been increasing interest in this subject (74,75), 
this issue remains incomplete in the same way as 
for pediatric RIs. To overcome this problem, a mul-
ticenter study which has extensive sample size 
from the pediatric, adult and geriatric age groups, 
is the best way to establish and harmonize the RIs 
across a country (76,77).
Laboratory RIs during pregnancy, delivery and the 
early postpartum period are another specific 
group as physiological changes during pregnancy 
may affect laboratory parameters and there is a 
need to establish reference values during preg-
nancy in order to recognize pathological condi-
tions (78). Reporting the correct gestational age-
specific reference values can also improve the sen-
sitivity of the RIs as mentioned before in this re-
view by stratification of age and gender.
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Partitioning by genetic effects on 
reference intervals
Integrating genetic and laboratory information 
would increase the accuracy of RIs by eliminating 
extreme results related to genetic variation. It has 
been reported that the use of genetic information 
to partition Rls could reduce the between-person 
variation and therefore with the reduced variance 
obtained from partitioning based on genetic dif-
ferences, there could be potentially less mis-iden-
tification of unusual test results caused by non-dis-
ease associated genetic variations (79). The genet-
ic information was used for subgroup stratification 
for ApoE (80) and more recently for haptoglobin 
(81). Ozarda et al. published a paper on methylene-
tetrahydrofolate reductase (MTHFR), and reported 
that serum folate and homocysteine status are im-
paired by subgroup stratification of the rate of 
MTHFR 677C > T i 1298A > C (82). However, the ex-
tent of biological variability induced by genetic 
variants is often low and there is often a lack of 
knowledge of the genetic status of the reference 
individuals. As whole-genome data becomes clini-
cally available and more associations between ge-
netic polymorphisms and laboratory test results 
are discovered, it will become possible to integrate 
the genetic information with RI values. 
The RIs for uncommon sample types [e.g. cerebro-
spinal fluids (CSF), amniotic fluids] are usually in-
terpreted on the basis of values reported in refer-
ence texts or handbooks; however, current refer-
ence texts either present normal CSF parameters 
without citation or cite studies with significant lim-
itations. Recent developments to determine accu-
rate, age-specific reference values for glucose, pro-
tein concentrations and white blood cell counts in 
CSF, amniotic fluids and aspirations in a large pop-
ulation of neonates and young infants will bring 
literature up to date at a time when molecular 
tools are commonly used in clinical practice 
(83,84).
Conclusion
Due to the increasing numbers of multi-centric 
studies in recent years, there was seen to be a 
need for a detailed protocol. IFCC, C-RIDL met this 
need with the publication of a very detailed proto-
col in 2014, which can be used when conducting 
multicentric studies. Based on this protocol a num-
ber of multicentric RI studies have been performed 
and common RIs have been reported. The com-
mon RIs reported in the multicenter study should 
be validated locally, using reference specimens 
from healthy individuials in the local population as 
recommended by C28-A3 and recent C-RIDL stud-
ies. 
Although indirect methods can be used as an al-
ternative, the problem of valid RIs for specific age 
groups (e.g. pediatric, geriatric) has not yet been 
resolved. Specific RI values for pregnant women 
and for uncommon samples are also necessary. It 
is vital that a clear distinction is made between RIs 
and CDLs to allow optimal use of laboratory tests 
and avoid misdiagnosis. Future studies should fo-
cus more specifically on the genetic effects on RIs 
and generate genotype-specific RIs. 
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